Replies to post #35042 on Relief Therapeutics Holding AG (RLFTF)

[Bill B]

This is from the article.

In a January 26 preprint paper, for example, researchers demonstrated that the SARS-CoV-2 variant that emerged in South Africa was "markedly more resistant" to antibodies in convalescent plasma, and "completely or markedly abolished" the activities of Lilly's bamlanivimab and Regeneron's casirivimab on their own. But Regeneron's imdevimab appeared to retain its function.